Inflammatory ocular adverse events with the use of oral bisphosphonates: A retrospective cohort study

CMAJ. Canadian Medical Association Journal

Volumn 184, Issue 8, 2012, Pages

  Etminan, Mahyar ^a,b   Forooghian, Farzin ^b   Maberley, David ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; EYE INFLAMMATION; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PHARMACOEPIDEMIOLOGY; PROPENSITY SCORE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCLERITIS; SENSITIVITY ANALYSIS; UVEITIS;

EID: 84861148411     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.111752     Document Type: Article

References (19)

1. Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011; 364:1728-37.
2. Heckbert SR, Li G, Cummings SR, et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008; 168:826-31. (Pubitemid 351649266)
3. Green J, Czanner G, Reeves G, et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010; 341: c4444.
4. Mercanti A, Parolini B, Bonora A, et al. Epidemiology of endogenous uveitis in north-eastern Italy. Analysis of 655 new cases. Acta Ophthalmol Scand 2001;79:64-8. (Pubitemid 32061039)
5. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 2004;111:491-500. (Pubitemid 38293104)
6. Tan YL, Sims J, Chee SP. Bilateral uveitis secondary to bisphosphonate therapy. Ophthalmologica 2009;223:215-6.
7. Malik AR, Campbell SH, Toma NM. Bilateral acute anterior uveitis after alendronate. Br J Ophthalmol 2002;86:1443. (Pubitemid 35408654)
8. Fraunfelder FW, Fraunfelder FT, Jensvold B. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 2003;135:219-22. (Pubitemid 36151800)
9. Mbekeani JN, Slamovits TL, Schwartz BH, et al. Ocular inflammation associated with alendronate therapy. Arch Ophthalmol 1999; 117:837-8. (Pubitemid 29265053)
10. French DD, Margo CE. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina 2008;28:889-93.
11. Huybrechts KF, Rothman KJ, Silliman RA, et al. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ 2011;183:E411-9.
12. Solomon DH, Massarotti E, Garg R, et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011; 305: 2525-31.
13. Fraunfelder FW. Drug-induced ocular inflammatory diseases. Drugs Today (Barc) 2007;43:117-23. (Pubitemid 46580872)
14. Ghose K, Waterworth R, Trolove P, et al. Uveitis associated with pamidronate. Aust N Z J Med 1994;24:320.
15. Hewitt RE, Lissina A, Green AE, et al. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 2005;139:101-11. (Pubitemid 40066134)
16. Thiébaud D, Sauty A, Burckhardt P, et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 1997;61:386-92.
17. de Smet MD, Taylor SR, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res 2011;30:452-70.
18. Cruess AF, Gordon KD, Bellan L, et al. The cost of vision loss in Canada. Can J Ophthalmol 2011;46:315-8.
19. Wells GA, Cranney A, Boucher M, et al. Bisphosphonates for the primary and secondary prevention of osteoporotic fractures in postmenopausal women: a meta-analysis [Technology report no. 69]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2006. Available: http://cadth. ca /media /pdf/371 -Bisphosphonates-tr-e-NoAppendix.pdf (accessed 2012 Mar. 2).